Cannabis and CBD for Osteoarthritis Pain: What the Evidence Really Shows
Cannabis-derived products are often promoted as alternatives for chronic pain, including osteoarthritis (OA). But while laboratory research provides a rationale for studying cannabinoids, clinical evidence has not established them as reliable treatments for OA pain.
Osteoarthritis is a degenerative joint disease involving cartilage, bone, and surrounding tissues. It can cause pain, stiffness, reduced mobility, and difficulty with daily activities. Established management typically combines therapeutic exercise, weight management when appropriate, self-management strategies, topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), and—in some cases—short-term corticosteroid injections. The American College of Rheumatology and Arthritis Foundation guideline strongly recommends exercise and several of these treatments for appropriate patients.
Cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), interact with biological pathways involved in pain perception and inflammation. Researchers have identified cannabinoid-related receptors in human osteoarthritic cartilage. In a laboratory study, cells in diseased cartilage expressed several of these receptors, suggesting that the tissue may respond to cannabinoid-based compounds. However, this finding shows biological plausibility—not that cannabis or CBD relieves pain in people or slows joint damage. The study of cannabinoid receptor expression in human osteoarthritic cartilage called for further research into targeted therapies that could avoid psychoactive effects.
Early clinical evidence has been mixed. A 2016 systematic review of randomized trials involving cannabinoids and rheumatic diseases found insufficient evidence to recommend cannabinoid preparations. Importantly, the review identified no randomized controlled trial specifically involving patients with osteoarthritis. Its findings concerning pain and sleep came largely from studies of fibromyalgia, spinal pain, and rheumatoid arthritis rather than OA. The full systematic review therefore does not support the stronger claim that cannabinoids had already been shown to reduce pain in people with osteoarthritis.
One frequently cited investigation was the 2018 STOP 1 trial of ZYN002, a synthetic CBD gel applied transdermally. The study randomized 320 adults with knee OA to two CBD doses or placebo for 12 weeks. Neither CBD dose produced a statistically significant improvement over placebo in the main measure of average worst knee pain. One lower-dose group did perform better in an additional responder analysis, but that result was exploratory and included other outcomes. The study record and conference abstract describe the results and their limitations.
Subsequent randomized trials have also failed to demonstrate a clear analgesic benefit. In a 2022 trial of 136 people with hand OA or psoriatic arthritis, synthetic CBD taken for 12 weeks did not improve pain, sleep, anxiety, depression, or pain-related distress more than placebo. The published trial report found almost identical pain outcomes between the CBD and placebo groups.
A 2023 trial provides especially relevant evidence for knee OA. Eighty-six participants continued taking paracetamol while receiving either 600 milligrams of oral CBD daily or placebo for eight weeks. Pain improved in both groups, but the difference between them was not statistically significant. Adverse events were more common with CBD, and elevations in liver-related blood tests occurred more often in the CBD group. The randomized, placebo-controlled knee OA trial concluded that the results did not support using high-dose CBD as an additional pain treatment.
These findings do not rule out the possibility that a particular cannabinoid, dose, or delivery method could eventually prove useful. Topical and transdermal products may have different effects from oral products, and small studies have produced signals that warrant further investigation. Yet studies of different formulations cannot be treated as interchangeable: CBD oil, synthetic CBD gel, THC-containing medicines, and whole-plant cannabis have different pharmacology, dosing, absorption, and safety profiles.
Safety also requires attention. Cannabis products containing THC can cause impairment, dizziness, sedation, and cognitive effects. CBD is not risk-free: the U.S. Food and Drug Administration warns about potential liver injury and drug interactions. Product strength and purity may vary, particularly outside regulated prescription medicines. People considering CBD or medical cannabis should discuss it with a clinician, especially if they take other medications, have liver disease, are at risk of falls, or need to drive or operate machinery.
The American Pain Society’s 2016 publication was a clinician-oriented consensus report about caring for patients who use cannabis; it was not evidence that cannabis had been proven effective for OA. Overall, current research supports continued study rather than routine use. For people with osteoarthritis, cannabinoid-based products should not replace treatments with stronger evidence, and any trial of such a product should be guided by an individualized discussion of potential benefits, risks, interactions, cost, and treatment goals.
